期刊
JOURNAL OF DERMATOLOGICAL SCIENCE
卷 88, 期 2, 页码 225-231出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.jdermsci.2017.07.007
关键词
Melanoma; Adverse event; Checkpoint inhibitor; White blood cell count; Blood cell parameters; Relative lymphocyte count
类别
Background: Although nivolumab significantly prolongs survival of metastatic melanoma, about 10% of patients experience severe, even fatal immune-related adverse events (irAEs). Biomarkers to predict irAEs are, therefore, of great interest. Objective: We aimed to correlate changes in routine blood count parameters to the occurrence of serious irAEs (grade 3/4 [G3/4] or lung/gastrointestinal [lung/GI] irAEs) in patients with melanoma who were treated with nivolumab. Methods: We retrospectively analyzed data from 101 patient with melanoma treated with nivolumab from 8 institutes in Japan. We used logistic regression analyses to investigate associations between severe irAEs and fluctuations in routine blood count parameters (total white blood cell [WBC] count, relative neutrophil, monocyte, lymphocyte, and eosinophil count) during the treatment. Receiver operating characteristic curve was used to determine a cutoff value for the blood count parameters and area under the curve (AUC). Results: Univariate analysis revealed that G3/4 irAEs were associated with increased total WBC count (P = 0.034, cutoff value = +27%, AUC= 0.68, odds ratio [OR] = 1.58) and decreased relative lymphocyte count (RLC, P= 0.042, cutoff value = -23%, AUC= 0.65, OR= 1.65). However, multivariate analysis showed that the same factors, increased WBC count (P = 0.014, cutoff value = +59.1%, AUC = 0.79, OR= 6.04) and decreased RLC (P = 0.012, cutoff value = 32.3%, AUC= 0.81, OR= 5.01) were independent factors associated with lung/GI irAEs. Conclusions: Our results suggest that increased WBC count and decreased RLC are associated with G3/4 and lung/GI irAEs. Our analysis was based on the data point at which irAE occurrence was noticed and, therefore, these factors are not predictive, however, they could be a signal of severe irAE occurrence in patients with melanoma treated with nivolumab. (C) 2017 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据